New hope for advanced breast cancer? drug combo trial launches
NCT ID NCT07002177
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tests a new drug called FWD1802 combined with other treatments for people with ER-positive/HER2-negative breast cancer that has spread or cannot be removed by surgery. About 196 participants will join to find safe doses and see if the combinations shrink tumors. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.